Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery
NCT ID: NCT00250237
Last Updated: 2009-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
220 participants
INTERVENTIONAL
2005-11-30
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium
NCT01862302
Preoperative Single Glucocorticoid Hip Fracture Hip Fracture Surgery
NCT02317601
Pharmacological Management of Delirium
NCT00842608
Combination of Haloperidol and Magnesium for Delirium Prevention in Critically Ill Elderly
NCT06168773
Post-operative Delirium (POD) in Patients Undergoing Hip Fracture Surgery
NCT05105906
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Patients receiving blinded medication (Haloperidol or Placebo)
Haloperidol
Haloperidol 1mg twice daily during 72hours
B
Patients receiving blinded medication (Haloperidol or Placebo)
placebo
Placebo 1mg twice daily during 72hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Haloperidol
Haloperidol 1mg twice daily during 72hours
placebo
Placebo 1mg twice daily during 72hours
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 75 years and older
Exclusion Criteria
* Pre-operative delirium
* Pre-operative use of haloperidol
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bronovo Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bronovo Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boke Linso Sjirk Borger van der Burg, MD
Role: PRINCIPAL_INVESTIGATOR
Bronovo Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bronovo Hospital
The Hague, South Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05-56
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.